Patent ID: 11964988
Assignee: ARRAY BIOPHARMA INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A compound of Formula I, wherein,
W is CR3R4,
 represents a single or a double bond, wherein when  is a double bond, then X is CR5 and Y is CR6, and when  is a single bond, then X is O, CR7R8 or NR9 and Y is C(═O), SO2, CR10R11 or O, and
Z is C or N;
R3 is hydrogen;
R4 is hydrogen;
R5 is hydrogen;
R6 is hydrogen;
R7 is hydrogen or C1-C6 alkyl;
R8 is hydrogen;
R9 is hydrogen, C1-C6 alkyl, hydroxyC1-C6 alkyl-, (C1-C6 alkyl)SO2—, (C1-C6 alkoxy)C1-C6 alkyl, C3-C6 cycloalkyl, (C3-C6 cycloalkyl)C1-C6 alkyl-, hetCyc1, (hetCyc1)C1-C6 alkyl-, Ar1, (Ar1)C1-C6alkyl-, hetAr1, (hetAr1)C1-C6 alkyl-, (C1-C6 alkyl)C(═O)—, (fluoroC1-C6 alkyl)C(═O)—, H2NC(═O)—, Ar1CH2C(═O)— or (C3-C6 cycloalkyl)C(═O)—;
R10 is hydrogen, hydroxy, C1-C6 alkoxy, or RaRbN— where Ra and Rb are independently H or C1-C6 alkyl;
R11 is hydrogen, C1-C6 alkyl, or fluoroC1-C6 alkyl;
hetCyc1 is a 5-6 membered saturated heterocyclic ring having 1-2 ring heteroatoms independently selected from N and SO2, wherein said heterocyclic ring is optionally substituted with C1-C6 alkyl or (Ar2)C1-C6 alkyl-;
Ar1 is phenyl optionally substituted with one or more substituents independently selected from halogen and C1-C6 alkoxy;
hetAr1 is a 5-6 membered heteroaryl ring having 1-2 ring nitrogen atoms, wherein said heteroaryl ring is optionally substituted with C1-C6 alkyl;
Ar2 is phenyl optionally substituted with one or more substituents independently selected from halogen and C1-C6 alkoxy;

Ring A, including the atoms at the points of attachment to the ring containing Z, Y, X, and W, is:
(i) a monocyclic aryl ring when Z is C, wherein said ring is optionally substituted with halogen, C3-C6 cycloalkyl, C1-C6 alkoxy, RcNHC(═O)—, RcC(═O)NH—, or RcNHC(═O)NH—,
(ii) a 5-membered monocyclic heteroaryl ring having 2 ring heteroatoms independently selected from N and O when Z is C, or when Z is N, a 5-membered heteroaryl ring having two ring nitrogen atoms, one of which is Z, wherein said rings are optionally substituted with C1-C6 alkyl or C3-C6 cycloalkyl, or
(iii) when Z is N, a bicyclic heteroaryl ring having one ring nitrogen atom which is Z, wherein said ring is optionally substituted with RdNHC(═O)—, (C1-C6 alkoxy)C(═O)—, C1-C6 alkyl, C1-C6 alkoxy, fluoroC1-C6 alkyl, CN, halogen, or (C1-C6 alkyl)C(═O)NH—;
Rc is C3-C6 cycloalkyl or (C3-C6 cycloalkyl)CH2—;
Rd is C1-C6 alkyl, C1-C6 alkoxy, Cyc1, Cyc1CH2—, phenyl or hetAr2;
Cyc1 is C3-C6 cycloalkyl optionally substituted with C1-C6 alkyl;
hetAr2 is (i) pyrazolyl optionally substituted with 1-2 substituents independently selected from C1-C6 alkyl, fluoroC1-C6 alkyl, (di-C1-C6 alkyl)NC(═O)CH2—, (hetCyc2)CH2CH2—, phenyl, and (C1-C6 alkoxy)C1-C6 alkyl, or (ii) pyridyl;
hetCyc2 is a 6-membered saturated heterocyclic ring having 2 ring heteroatoms independently selected from N and O;
Rx is hydrogen, C1-C6 alkyl, fluoroC1-C6 alkyl, Cyc2, Cyc3, hetCyc3, Ar3 or hetAr3;
Cyc2 is a 3-6 membered saturated carbocyclic ring optionally substituted with 1-2 substituents independently selected from halogen, C1-C6 alkyl, hydroxy, hydroxyC1-C6 alkyl, and (C1-C6 alkoxy)C(═O)—;
Cyc3 is cyclopentenyl;
hetCyc3 is a 5-membered saturated heterocyclic ring having a ring heteroatom selected from N and O and optionally substituted with (C1-C6 alkyl)C(═O)—;
Ar3 is phenyl optionally substituted with (C1-C6 alkoxy)C(═O)—;
hetAr3 is a 5-6 membered heteroaryl ring having 1-2 ring nitrogen atoms and optionally substituted with C1-C6 alkyl or C1-C6 alkoxy; and
Ry is hydrogen or halogen;
or a pharmaceutically acceptable salt thereof.